Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
Background Pirfenidone and nintedanib are the only disease-modifying treatments available for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in clinical practice.Methods This is a single-centre retrospective observational study undertaken at a specialised int...
Saved in:
| Main Authors: | Dhruv Parekh, David R Thickett, Peter Nightingale, Louise E Crowley, Anjali Crawshaw, William Alexander Wright |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-01-01
|
| Series: | BMJ Open Respiratory Research |
| Online Access: | https://bmjopenrespres.bmj.com/content/8/1/e000782.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neutrophil dynamics in pulmonary fibrosis: pathophysiological and therapeutic perspectives
by: Louise Elizabeth Crowley, et al.
Published: (2024-11-01) -
Evaluation of Antifibrotic Mechanisms of 3′5-Dimaleamylbenzoic Acid on Idiopathic Pulmonary Fibrosis: A Network Pharmacology and Molecular Docking Analysis
by: Karina González-García, et al.
Published: (2024-12-01) -
Gender Differences Are a Leading Factor in 5-Year Survival of Patients with Idiopathic Pulmonary Fibrosis over Antifibrotic Therapy Reduction
by: Pasquale Tondo, et al.
Published: (2025-01-01) -
Pretreatment with G-CSF Could Enhance the Antifibrotic Effect of BM-MSCs on Pulmonary Fibrosis
by: Feiyan Zhao, et al.
Published: (2019-01-01) -
Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
by: Mark L. Wencel, et al.
Published: (2018-06-01)